Treatment with LAB (n = 6), losartan (n = 6), or amlodipine had no effect on the body weight gain compared with PBS treated OLETF control rats (n = 6). * P < 0.05 compared with LETO (n = 6).
Fig. 2.
Profiles of systolic blood pressure change. OLETF rats progressively developed hypertension, whereas treatment with either losartan (n = 6), amlodipine (n = 6), or LAB (n = 6) reduced systolic blood pressure significantly. Treatment with losartan and amlodipine resulted in similar reductions in SBP, while treatment with LAB had a less potent effect on lowering blood pressure. * P < 0.05 compared with LETO (n = 6), †P < 0.05 compared with PBS treated OLETF (n = 6). a and b represent P < 0.05. Values are means ± SE. AST, Aspartate aminotransferase; ALT, Alanine aminotransferase. * P < 0.05 compared to LETO; †P < 0.05 compared to OLETF.
LAB 투여는 OLETF대조군에 비해서 MCP-1발현을 약 57% 정도로 감소시켰다 (Fig. 4) . Angiotensinogen mRNA expression profile. At 38 weeks of age, OLETF rat showed higher renal renin and angiotensinogen mRNA levels than LETO rats. Treatment with losartan (n = 6) significantly increased renin mRNA levels but had no effect on angiotensinogen mRNA levels in OLETF rats. Treatment with amlodipine (n = 6) or LAB (n = 6) had no significant effects on renin and angiotensinogen mRNA expression level in OLETF rats. Values are means ± SE. * P < 0.05 compared with LETO (n = 6), †P < 0.05 compared with PBS treated OLETF (n = 6). Only treatment with LAB caused a decrease in renal cortical MCP-1 mRNA expression levels. LAB decreased amount of MCP-1 expression to the 57% level of PBS treated OLETF control (n = 6).
Fig. 5.
Profiles of glucose tolerance test at 38 weeks. Blood glucose levels were the greatest 30 min after the intraperitoneal glucose injection in all animals, which was followed by a distinct disposal phase. There was a delay in blood glucose disposal in OLETF rats. Treatment with LAB (n = 6), losartan (n = 6), or amlodipine (n = 6) did not significantly influence fasting and postprandial plasma glucose levels. * P < 0.05 compared with LETO (n = 6).
대조군에 비해 유의하게 감소하였으나 amlodipine투여군
에서는 유의한 감소가 없었다 (Fig. 6 ).
신장피질에서 TGF-β1단백질 발현에 대한 효과
TGF-β1의 정량적 분석결과 losartan과 LAB투여는 강력하 게 신피질의 TGF-β1 단백발현을 감소시켰으나 amlodipine 투여군에서는 유의한 효과를 관찰할 수 없었다 (Fig. 7) . (Table 1) . Fig. 6 . Effects on albuminuria. The amount of albuminuria was markedly suppressed by treatment with losartan (n = 6) and LAB (n = 6), but not with amlodipine (n = 6). Values are means ± SE. * P < 0.05 compared with LETO (n = 6), †P < 0.05 compared with OLETF (n = 6). 참 고 문 헌 , pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 45:1345-59, 2005 
